These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37845427)

  • 1. Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study.
    Yasaka M; Yokota H; Suzuki M; Asakura H; Yamane T; Ogi Y; Kimoto T; Nakayama D
    Cardiol Ther; 2023 Dec; 12(4):723-740. PubMed ID: 37845427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study.
    Yasaka M; Yokota H; Suzuki M; Asakura H; Yamane T; Ogi Y; Ochiai K; Nakayama D
    Cardiol Ther; 2020 Jun; 9(1):167-188. PubMed ID: 32152956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence Rates of Bleeding and Emergency Surgery Due to Trauma or Fracture Among Japanese Patients with Non-valvular Atrial Fibrillation Receiving Oral Anticoagulation Therapy.
    Yasaka M; Yokota H; Suzuki M; Yamane T; Ono Y
    Cardiol Ther; 2020 Jun; 9(1):189-199. PubMed ID: 32394292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2.
    Yamashita T; Uchiyama S; Atarashi H; Okumura K; Koretsune Y; Yasaka M; Wakayama J; Fukaya T; Inoue H;
    J Cardiol; 2022 Sep; 80(3):255-260. PubMed ID: 35717283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
    Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
    Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
    Van der Wall SJ; Lopes RD; Aisenberg J; Reilly P; van Ryn J; Glund S; Elsaesser A; Klok FA; Pollack CV; Huisman MV
    Circulation; 2019 Feb; 139(6):748-756. PubMed ID: 30586692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
    Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
    Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P
    Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
    Pollack CV; Reilly PA; van Ryn J; Eikelboom JW; Glund S; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Royle G; Sellke FW; Stangier J; Steiner T; Verhamme P; Wang B; Young L; Weitz JI
    N Engl J Med; 2017 Aug; 377(5):431-441. PubMed ID: 28693366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
    Pollack CV
    Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two Dabigatran Fast Reversals in a 4-month Period - a Case Report.
    Fagundes V; Mesquita M
    Eur J Case Rep Intern Med; 2019; 6(12):001311. PubMed ID: 31893202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarucizumab for Dabigatran Reversal.
    Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
    N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N; Morrill AM; Willett KC
    Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study.
    Yasaka M; Ikushima I; Harada A; Imazu S; Taniguchi A; Norris S; Gansser D; Stangier J; Schmohl M; Reilly PA
    Res Pract Thromb Haemost; 2017 Oct; 1(2):202-215. PubMed ID: 30046691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence supporting idarucizumab for the reversal of dabigatran.
    Pollack CV
    Am J Emerg Med; 2016 Nov; 34(11S):33-38. PubMed ID: 27697436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experience with idarucizumab as a reverse agent of dabigatran].
    Bottaro FJ; Margan MM; Duboscq C; Ceresetto JM
    Medicina (B Aires); 2020; 80(4):405-410. PubMed ID: 32841148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study.
    Wang Z; Zhao X; He P; Chen S; Jiang J; Harada A; Brooks S; Cui Y
    Adv Ther; 2020 Sep; 37(9):3916-3928. PubMed ID: 32691242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation.
    Okishige K; Yamauchi Y; Hanaki Y; Inoue K; Tanaka N; Yamaji H; Murakami T; Manita M; Tabata K; Ooie T; Tatsukawa Y; Sakai H; Yamaki M; Murakami M; Takada T; Osaka Y; Ono Y; Handa K; Sugiyama K; Yoshizawa T; Fukaya H; Tashiro H; Takase S; Harada M; Watanabe E; Yamane T; Yamashita S; Aonuma K
    J Thromb Thrombolysis; 2019 May; 47(4):487-494. PubMed ID: 30955142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
    Vosko MR; Bocksrucker C; Drwiła R; Dulíček P; Hauer T; Mutzenbach J; Schlimp CJ; Špinler D; Wolf T; Zugwitz D
    J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.